Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
44.55
+0.11 (0.25%)
Feb 4, 2026, 2:55 PM CST
SHE:300584 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 76.14 | 45.76 | 46.82 | 95.07 | 115.6 | 103.23 |
Trading Asset Securities | - | - | - | - | - | 10 |
Cash & Short-Term Investments | 76.14 | 45.76 | 46.82 | 95.07 | 115.6 | 113.23 |
Cash Growth | 99.34% | -2.27% | -50.75% | -17.76% | 2.09% | -24.57% |
Accounts Receivable | 184.22 | 200.56 | 207.7 | 190.71 | 113.31 | 101.69 |
Other Receivables | 0.47 | 0.08 | 0.13 | 18.24 | 10.48 | 5.57 |
Receivables | 184.69 | 200.64 | 207.82 | 208.95 | 123.79 | 107.26 |
Inventory | 76.2 | 85.67 | 81.46 | 64.13 | 55.16 | 71.58 |
Prepaid Expenses | - | - | - | 0.23 | 0.23 | 0.16 |
Other Current Assets | 15.41 | 25.08 | 41.19 | 9.99 | 7.17 | 1.52 |
Total Current Assets | 352.44 | 357.15 | 377.3 | 378.38 | 301.96 | 293.74 |
Property, Plant & Equipment | 811.36 | 763.73 | 646.76 | 505.53 | 370.75 | 310.81 |
Long-Term Investments | 136.8 | 131.46 | 131.46 | 190.7 | 437.58 | 129.95 |
Other Intangible Assets | 123.37 | 140.8 | 126.77 | 134.01 | 122.33 | 92.23 |
Long-Term Deferred Tax Assets | 28.52 | 25.49 | 21.84 | 16.6 | 11.76 | 8.38 |
Long-Term Deferred Charges | 5 | 10.6 | 41.54 | 37.32 | 50.59 | 52.51 |
Other Long-Term Assets | 25.89 | 35.31 | 63.21 | 31.4 | 7.04 | 18.9 |
Total Assets | 1,483 | 1,465 | 1,409 | 1,294 | 1,302 | 906.52 |
Accounts Payable | 52.58 | 33.74 | 63.95 | 59.89 | 80.26 | 20.69 |
Accrued Expenses | 0.35 | 31.83 | 28.61 | 20.81 | 17.05 | 14.92 |
Short-Term Debt | 198.25 | 230.26 | 252.98 | 120.1 | 100.11 | 70.08 |
Current Portion of Long-Term Debt | 52.96 | 12.18 | 18.02 | 58.06 | 80.09 | 60.74 |
Current Portion of Leases | - | - | - | - | 0.08 | - |
Current Income Taxes Payable | 23.89 | 2.12 | 5.38 | 17.16 | 0.98 | 0.71 |
Current Unearned Revenue | 1.6 | 2.35 | 3.36 | 1.74 | 7.21 | 4.81 |
Other Current Liabilities | 19.87 | 22.88 | 27.97 | 39.29 | 15.64 | 9.03 |
Total Current Liabilities | 349.51 | 335.35 | 400.27 | 317.05 | 301.43 | 180.97 |
Long-Term Debt | 45.4 | 72.3 | - | - | - | 39.38 |
Long-Term Unearned Revenue | 6.06 | 6.24 | 6.48 | 8.48 | 10.64 | 7.2 |
Long-Term Deferred Tax Liabilities | 8.44 | 12.48 | 14.62 | 17.85 | 41.47 | - |
Total Liabilities | 410.14 | 426.37 | 421.37 | 343.38 | 353.53 | 227.55 |
Common Stock | 120 | 120 | 120 | 120 | 120 | 120 |
Additional Paid-In Capital | 211.34 | 211.49 | 210.29 | 210.29 | 212.46 | 212.46 |
Retained Earnings | 711.39 | 690.71 | 656.49 | 620.17 | 617.72 | 346.85 |
Comprehensive Income & Other | 0.61 | 0.74 | 0.72 | 0.11 | 0.14 | 0.47 |
Total Common Equity | 1,043 | 1,023 | 987.5 | 950.57 | 950.33 | 679.77 |
Minority Interest | 29.91 | 15.24 | - | - | -1.85 | -0.8 |
Shareholders' Equity | 1,073 | 1,038 | 987.5 | 950.57 | 948.48 | 678.97 |
Total Liabilities & Equity | 1,483 | 1,465 | 1,409 | 1,294 | 1,302 | 906.52 |
Total Debt | 297.34 | 314.74 | 271 | 178.15 | 180.28 | 170.19 |
Net Cash (Debt) | -221.19 | -268.98 | -224.18 | -83.09 | -64.68 | -56.96 |
Net Cash Per Share | -1.84 | -2.24 | -1.87 | -0.69 | -0.54 | -0.47 |
Filing Date Shares Outstanding | 120 | 120 | 120 | 120 | 120 | 120 |
Total Common Shares Outstanding | 120 | 120 | 120 | 120 | 120 | 120 |
Working Capital | 2.93 | 21.8 | -22.97 | 61.33 | 0.53 | 112.77 |
Book Value Per Share | 8.69 | 8.52 | 8.23 | 7.92 | 7.92 | 5.66 |
Tangible Book Value | 919.96 | 882.13 | 860.73 | 816.55 | 828 | 587.55 |
Tangible Book Value Per Share | 7.67 | 7.35 | 7.17 | 6.80 | 6.90 | 4.90 |
Buildings | - | 252.62 | 251.11 | 251.11 | 241.79 | 229.35 |
Machinery | - | 172.2 | 227.36 | 230.08 | 189.93 | 184.45 |
Construction In Progress | - | 551.83 | 381.52 | 206.08 | 95.06 | 21.24 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.